Tag:

Johnson & Johnson

Latest Headlines

Latest Headlines

Evotec banks $10M from its risk-sharing research projects

German contract developer Evotec pocketed €8 million ($10 million) from its ongoing R&D collaborations with Bayer and Johnson & Johnson, capping a big year for the innovative company.

J&J rents Halozyme's R&D technology for up to $581M

Johnson & Johnson has signed a deal to use Halozyme Therapeutics' drug delivery platform in its own R&D efforts, agreeing to pay as much as $581 million for the privilege.

J&J punts a pair of new IBD drugs discovered at Galapagos

A few weeks ago Belgium's Galapagos touted some early-stage data on GLPG1205, a new drug for inflammatory bowel diseases which it discovered under a $1 billion-plus partnership deal inked with J&J back in 2007. But today J&J bowed out of the pact for the entire GPR84 program, an effort that includes GLPG1205 and its backup compound GLPG2196.

Novartis psoriasis prospect tops J&J's fast-growing Stelara in PhIII

J&J's Stelara has some psoriasis competition waiting in the wings: On Friday, Novartis announced its Phase III prospect, to be marketed as Cosentyx, had bested the drug in a head-to-head trial.

J&J discount offer wins NICE over to new use for Stelara

The National Institute for Health and Care Excellence decided to reverse course on a new use for Johnson & Johnson's anti-inflammatory drug Stelara, thanks to a new discount offer.

J&J gains FDA clearance for rare pediatric spinal device

The FDA has cleared the VEPTR and VEPTR II Vertical Expandable Prosthetic Titanium Rib Devices to treat children with thoracic insufficiency syndrome, a rare congenital condition that results in severe deformities of the chest, spine or ribs that impair breathing and lung growth.

Covidien loses battle in patent war with J&J as top U.S. patent court throws out $176M award

Covidien lost a battle in its years-long patent war with Johnson & Johnson's Ethicon unit, as a top U.S. patent appeals court tossed out a $176 million award for the company and ruled that its claims regarding J&J/Ethicon's Harmonic line ultrasonic surgical tools were invalid.

J&J launches PhII lymphoma study for daratumumab

Genmab reports that its partners at J&J are starting a Phase II study of daratumumab in non-Hodgkin's lymphoma.

Bayer and J&J push back against consolidation of Xarelto suits

Bayer and Johnson & Johnson are fighting a consolidation of lawsuits over their top-selling anticoagulant Xarelto, months after patients filed suit in the U.S. accusing the companies of downplaying the drug's risks.

Astellas' Xtandi to challenge J&J's Zytiga in the EU with pre-chemo OK

After ringing up a key U.S. approval in September to threaten Johnson & Johnson's Zytiga, Astellas' Xtandi now has what it needs to ramp up its market-share battle in the EU, too.